Journal
INTERVIROLOGY
Volume 54, Issue 3, Pages 105-112Publisher
KARGER
DOI: 10.1159/000320197
Keywords
Phage-based nanoparticles; Cervical cancer; Gene therapy; Human papillomavirus E7; C57BL/6 mice
Categories
Ask authors/readers for more resources
Objective: Human papillomavirus (HPV) oncoproteins (i.e. E6 and E7) are constitutively expressed in cervical cancer cells. The proteins are ideal targets to be used for developing therapeutic vaccines against existing HPV-associated carcinomas. To date, whole bacteriophage ('phage')-lambda particles, rather than purified 'naked' DNA, have been described as highly efficient delivery vehicles for a DNA vaccine. Methods: In this study, a safe and efficient lambda-based therapeutic cancer vaccine, recombinant lambda-ZAP E7 phage, was developed by inserting a HPV16 E7 gene into the Lambda ZAP (R) cytomegalovirus vector. lambda-ZAP E7 phages were employed to immunize mice against the E7-expressing murine tumor cell line (TC-1), which is used as a tumor model in an H-2b murine system. Results: The tumor-bearing mice indicated a significant inhibition of tumor growth after 3 injections of 2 x 10(12) particles of recombinant phages. Released lactate dehydrogenase, interferon-lambda and granzyme B from spleen cells and lymphocyte proliferation of spleen cells, which all demonstrate the enhancement of cell-mediated immunity, suggested the phages could be a potent gene delivery system in animal models. Conclusion: Our results suggest the recombinant phages can be used as effective biological tools for inducing E7-specific protective immune responses. Hence, the study introduces a possible therapeutic strategy against cervical cancer and other HPV-related neoplasia. Copyright (C) 2010 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available